Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.37 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.37 |
| ▸ | HNF4A | P41235 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL950980 | 0.86 | KCNH2 (0.48) | RNASEH1HPSESMN1; SMN2 | |
| SCHEMBL949054 | 0.83 | HDAC1 (0.44) | LMNARAB9AHPSESMN1; SMN2 | |
| SCHEMBL20477417 | 0.82 | SMN1; SMN2 (0.56) | LMNAGAARAB9ATSHRSMN1; SMN2 | |
| SCHEMBL7936688 | 0.77 | CALM1 (0.41) | BRD4HCAR2RNASEH1FEN1GAA | |
| SCHEMBL29956837 | 0.76 | HCAR2 (0.33) | HCAR2LMNA | |
| Phenylalanine SCHEMBL1701460 | 0.75 | SLC7A5 (0.54) | LMNATSHRHIF1A | |
| SCHEMBL7372940 | 0.75 | BRD4 (0.33) | BRD4LMNAPLA2G10PLA2G2A | |
| SCHEMBL1723556 | 0.74 | TAAR1 (0.48) | POLBGAARAB9ACALM1TSHR | |
| SCHEMBL7455986 | 0.74 | POLB (0.39) | BRD4POLBFEN1GAACALM1 | |
| SCHEMBL4081720 | 0.74 | TAAR1 (0.41) | BRD4RNASEH1POLBFEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-20110015371-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-20 | — | — | US | disclosed |
| US-7772366-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2123665-A2 | Inhibitors of interleukin-1Beta converting enzyme | Vertex Pharmaceuticals Incorporated (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-2076496-A1 | AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008046756-A1 | AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | disclosed |
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-7288624-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-30 | — | — | US | disclosed |
| CN-1192035-C | Inhibitors of interleukin-1'beta' converting enzyme | VERTEX PHARMA (US) | 2005-03-09 | — | — | CN | disclosed |
| EP-1394175-A1 | Inhibitors of interleukin-1beta converting enzyme | Vertex Pharmaceuticals Incorporated (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20020099042-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-25 | — | — | US | disclosed |
| US-6420522-B1 | ENZYME INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-16 | — | — | US | disclosed |
| US-6103711-A | INTERLEUKIN-1 MEDIATED DISEASES; ANTIINFLAMMATORY AND -CARCINOGENIC AGENTS; AUTOIMMUNE AND NEURODEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2000-08-15 | — | — | US | disclosed |
| US-5973111-A | NOVEL COMPOUNDS THAT ARE CAPABLE OF BINDING TO THE ACTIVE SITE OF INTERLEUKIN-1B-CONVERTING ENZYME (ICE) AND INHIBITING ACTIVITY OF THAT ENZYME; ADMINISTERING TO TREAT INFLAMMATORY, AUTOIMMUNE, AND NEURODEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5847135-A | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-12-08 | — | — | US | disclosed |
| US-5716929-A | THERAPY FOR INFLAMMATION, AUTOIMMUNE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1998-02-10 | — | — | US | disclosed |
| CN-1159196-A | Inhibitors of interleukin-1'beta' converting enzyme | VERTEX PHARMA (US) | 1997-09-10 | — | — | CN | disclosed |
| US-5656627-A | USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE AND NEURODEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| EP-0784628-A1 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1997-07-23 | — | — | EP | disclosed |
| WO-1995035308-A1 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | BRD4 2829/4885HCAR2 1919/4885RNASEH1 315/4885 |
| US-20020099042-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1RN | BRD4 2900/4885HCAR2 1948/4885RNASEH1 319/4885 |
| US-20110015371-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | BRD4 2829/4885HCAR2 1919/4885RNASEH1 315/4885 |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | BRD4 2829/4885HCAR2 1919/4885RNASEH1 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.